170 related articles for article (PubMed ID: 32677106)
1. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study.
Qureshi MY; Patterson MC; Clark V; Johnson JN; Moutvic MA; Driscoll SW; Kemppainen JL; Huston J; Anderson JR; Badley AD; Tebben PJ; Wackel P; Oglesbee D; Glockner J; Schreiner G; Dugar S; Touchette JC; Gavrilova RH
J Inherit Metab Dis; 2021 Mar; 44(2):502-514. PubMed ID: 32677106
[TBL] [Abstract][Full Text] [Related]
2. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
Zesiewicz T; Salemi JL; Perlman S; Sullivan KL; Shaw JD; Huang Y; Isaacs C; Gooch C; Lynch DR; Klein MB
Neurodegener Dis Manag; 2018 Aug; 8(4):233-242. PubMed ID: 30051753
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatments for Friedreich ataxia.
Kearney M; Orrell RW; Fahey M; Brassington R; Pandolfo M
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD007791. PubMed ID: 27572719
[TBL] [Abstract][Full Text] [Related]
5. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
Jain P; Badgujar L; Spoorendonk J; Buesch K
Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.
Velasco-Sánchez D; Aracil A; Montero R; Mas A; Jiménez L; O'Callaghan M; Tondo M; Capdevila A; Blanch J; Artuch R; Pineda M
Cerebellum; 2011 Mar; 10(1):1-8. PubMed ID: 20865357
[TBL] [Abstract][Full Text] [Related]
7. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
Meier T; Perlman SL; Rummey C; Coppard NJ; Lynch DR
J Neurol; 2012 Feb; 259(2):284-91. PubMed ID: 21779958
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal gait and balance decline in Friedreich's Ataxia: A pilot study.
Zesiewicz TA; Stephenson JB; Kim SH; Sullivan KL; Jahan I; Huang Y; Salemi JL; Wecker L; Shaw JD; Gooch CL
Gait Posture; 2017 Jun; 55():25-30. PubMed ID: 28411441
[TBL] [Abstract][Full Text] [Related]
9. Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study.
Legrand L; Weinsaft JW; Pousset F; Ewenczyk C; Charles P; Hatem S; Heinzmann A; Biet M; Durr A; Redheuil A
Arch Cardiovasc Dis; 2022 Jan; 115(1):17-28. PubMed ID: 34920960
[TBL] [Abstract][Full Text] [Related]
10. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.
Hausse AO; Aggoun Y; Bonnet D; Sidi D; Munnich A; Rötig A; Rustin P
Heart; 2002 Apr; 87(4):346-9. PubMed ID: 11907009
[TBL] [Abstract][Full Text] [Related]
11. Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited.
Schwabova J; Maly T; Laczo J; Zumrova A; Komarek V; Musova Z; Zahalka F
J Neurol Sci; 2014 Jun; 341(1-2):64-7. PubMed ID: 24768059
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Biomarkers in Friedreich's Ataxia: a Systematic Review and Meta-analysis.
Gavriilaki M; Chatzikyriakou E; Moschou M; Arnaoutoglou M; Sakellari I; Kimiskidis VK
Cerebellum; 2024 Jun; 23(3):1184-1203. PubMed ID: 37889470
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction.
St John Sutton M; Ky B; Regner SR; Schadt K; Plappert T; He J; D'Souza B; Lynch DR
Echocardiography; 2014; 31(1):50-7. PubMed ID: 23834395
[TBL] [Abstract][Full Text] [Related]
16. Characterizing gait, locomotor status, and disease severity in children and adolescents with Friedreich ataxia.
Croarkin E; Maring J; Pfalzer L; Harris-Love M; Siegel K; DiProspero N
J Neurol Phys Ther; 2009 Sep; 33(3):144-9. PubMed ID: 19809393
[TBL] [Abstract][Full Text] [Related]
17. Morphologic and functional characteristics of the heart in Friedreich's ataxia.
Unverferth DV; Schmidt WR; Baker PB; Wooley CF
Am J Med; 1987 Jan; 82(1):5-10. PubMed ID: 3799693
[TBL] [Abstract][Full Text] [Related]
18. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
Lagedrost SJ; Sutton MS; Cohen MS; Satou GM; Kaufman BD; Perlman SL; Rummey C; Meier T; Lynch DR
Am Heart J; 2011 Mar; 161(3):639-645.e1. PubMed ID: 21392622
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial.
Arpa J; Sanz-Gallego I; Rodríguez-de-Rivera FJ; Domínguez-Melcón FJ; Prefasi D; Oliva-Navarro J; Moreno-Yangüela M
Acta Neurol Scand; 2014 Jan; 129(1):32-40. PubMed ID: 23668357
[TBL] [Abstract][Full Text] [Related]
20. Idebenone in Friedreich's ataxia.
Tonon C; Lodi R
Expert Opin Pharmacother; 2008 Sep; 9(13):2327-37. PubMed ID: 18710357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
